Corporate News Report – Canadian Uranium Inc. (CANU.CN)
Trading Activity (24‑Hour Period Ending 10:21 PM Central Europe, Tuesday 20 Oct 2026)
| Metric | Value |
|---|---|
| Closing price | CAD 1.10 |
| 24‑hour change | –4.35 % |
| 24‑hour volume | CAD 31.6 k |
| 24‑hour market cap | CAD 34.1 mn |
| Shares outstanding | 29.6 mn |
| 200‑day simple moving average | CAD 1.00 |
| 52‑week high | CAD 1.59 (25 Mar 2026) |
| 52‑week low | CAD 0.20 (31 Oct 2025) |
| Monthly change (from last month‑end) | –7.56 % |
Market Position
Canadian Uranium Inc. trades on popular exchanges at a price of approximately CAD 1.10 per share. The company’s market capitalization is CAD 34.1 million. The average trading price over the last 200 days is CAD 1.00, indicating that the current price is slightly above the medium‑term trend.
Comparative Performance of Related Stocks (Last 24 Hours)
| Ticker | Current price | 24‑hour change | Market cap | Notable commentary |
|---|---|---|---|---|
| IEI.V (Imperial Equities) | CAD 4.25 | 0 % | CAD 40.2 mn | PE = 8.77 |
| ZYUS.V (Zyus Life Sciences) | CAD 0.50 | 0 % | CAD 40.3 mn | — |
| PUR.V (Premier American Uranium) | CAD 0.37 | –1.2 % | CAD 39.7 mn | Active drilling at Kaycee and Cebolleta projects; preliminary economic assessment underway; partnership with DISA Uranium pending regulatory approval |
| MMP-UN.TO (Precious Metals & Mining Tru) | CAD 4.03 | +2.03 % | CAD 40.4 mn | PE = 2.36 |
| BNXT.CN (BioNxt) | CAD 0.28 | –5 % | CAD 40.8 mn | Completed GMP production of sublingual Cladribine film; filed EU clinical trial application |
Company Overview – Free Battery Metal Ltd. (Canadian Uranium Inc.)
Free Battery Metal Ltd. is a Canadian mining company focused on the exploration and extraction of battery metals. Its primary operations are listed on the Canadian National Stock Exchange, a major Canadian stock exchange. The company’s strategy includes developing battery‑metal resources to meet growing demand in the renewable energy sector.
Summary
The trading session ending on 20 October 2026 saw Canadian Uranium Inc. decline by 4.35 % to CAD 1.10 per share. The stock’s price remains above its 200‑day average but below its 52‑week high. Compared with peer companies, Canadian Uranium’s performance is consistent with a modest decline, while some peers (e.g., Precious Metals & Mining Tru) recorded gains. Premier American Uranium continues to advance exploration projects in the United States, and BioNxt is progressing clinical development of a sublingual drug formulation.
